This activity is designed for surgeons and researchers interested in learning about intraoperative molecular imaging. This includes surgical oncologists, neuro-surgeons, thoracic surgeons, gynecologic oncology surgeons, gastrointestinal surgeons, otorhinolaryngologists/head and neck cancer surgeons, and other healthcare professionals involved in intraoperative molecular imaging for cancer such as radiologists, physicists, engineers, research scientists, technologists.
Upon completion of this course, participants should be able to:
- Describe the status of ongoing or completed clinical trials in the field of intraoperative molecular imaging for cancer surgery
- Define indications and endpoints for intraoperative imaging trials in clinical cancer surgery
- Explore opportunities for creation of surgeon billing codes (CPT) for intraoperative molecular imaging
In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation of Credit
- Physicians: Penn Medicine designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 8.25 Category 1 credits for completing this activity.
To learn more, download the event brochure (PDF)
Disclosures: Penn Medicine, Office of Continuing Medical and Interprofessional Education, adheres to the ACCME Standards for Commercial Support. Faculty and planner’s disclosure information will be made available in the conference materials and syllabus. Faculty members are also expected to disclose to participants any discussion of off-label and / or investigational use of pharmaceutical products or devices within their presentations.